当前位置: 首页 >> 检索结果
302. HepB-CpG vs HepB-Alum Vaccine in People With HIV and Prior Vaccine Nonresponse: The BEe-HIVe Randomized Clinical Trial.
作者: Kristen M Marks.;Minhee Kang.;Triin Umbleja.;Andrea Cox.;Karen J Vigil.;Ngan T Ta.;Ayotunde Omoz-Oarhe.;Hugo Perazzo.;Josphat Kosgei.;Timothy Hatlen.;Jennifer Price.;Leolin Katsidzira.;Khuanchai Supparatpinyo.;Kevin Knowles.;Beverly L Alston-Smith.;Parita Rathod.;Kenneth E Sherman.; .
来源: JAMA. 2025年333卷4期295-306页
Nonresponse to hepatitis B vaccine is common among people with HIV, resulting in vulnerability to infection with hepatitis B virus (HBV).
304. Intravenous Lidocaine for Gut Function Recovery in Colonic Surgery: A Randomized Clinical Trial.
作者: Hugh Paterson.;Thenmalar Vadiveloo.;Karen Innes.;Angie Balfour.;Marek Atter.;Andrew Stoddart.;Seonaidh Cotton.;Robert Arnott.;Lorna Aucott.;Zoe Batham.;Irwin Foo.;Graeme MacLennan.;Susan Nimmo.;Doug Speake.;John Norrie.
来源: JAMA. 2025年333卷1期39-48页
Despite the recovery advantages of minimally invasive surgical techniques, delayed return of gut function after colectomy is a common barrier to timely discharge from hospital.
307. Transcatheter Edge-to-Edge Repair for Severe Isolated Tricuspid Regurgitation: The Tri.Fr Randomized Clinical Trial.
作者: Erwan Donal.;Julien Dreyfus.;Guillaume Leurent.;Augustin Coisne.;Pierre-Yves Leroux.;Anne Ganivet.;Catherine Sportouch.;Yoan Lavie-Badie.;Patrice Guerin.;Frédéric Rouleau.;Christelle Diakov.;Jan van der Heyden.;Stéphane Lafitte.;Jean-François Obadia.;Mohammed Nejjari.;Nicole Karam.;Anne Bernard.;Antoinette Neylon.;Romain Pierrard.;Didier Tchetche.;Said Ghostine.;Gregory Ducrocq.;Thiziri Si Moussi.;Antoine Jeu.;Marcel Peltier.;Bernard Cosyns.;Yvan Le Dolley.;Gilbert Habib.;Vincent Auffret.;Florent Le Ven.;François Picard.;Nicolas Piriou.;Thierry Laperche.;Elena Galli.;Sabina Istratoaie.;Jerome Jouan.;Guillaume Bonnet.;Pascal de Groote.;Amedeo Anselmi.;Jean-Noel Trochu.;Emmanuel Oger.; .
来源: JAMA. 2025年333卷2期124-132页
Correction of tricuspid regurgitation using tricuspid transcatheter edge-to-edge repair (T-TEER) in addition to guideline-directed optimized medical therapy (OMT) may improve clinical outcomes.
308. Association of Severe Maternal Morbidity With Subsequent Birth.
作者: Eleni Tsamantioti.;Anna Sandström.;Charlotte Lindblad Wollmann.;Jonathan M Snowden.;Neda Razaz.
来源: JAMA. 2025年333卷2期133-142页
Women who experience severe maternal morbidity (SMM) might have lasting health issues, and the association of SMM with the probability of future reproductive intentions is unknown.
312. Zerlasiran-A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial.
作者: Steven E Nissen.;Qiuqing Wang.;Stephen J Nicholls.;Ann Marie Navar.;Kausik K Ray.;Gregory G Schwartz.;Michael Szarek.;Erik S G Stroes.;Roland Troquay.;Jannick A N Dorresteijn.;Henry Fok.;David A Rider.;Steven Romano.;Kathy Wolski.;Curtis Rambaran.
来源: JAMA. 2024年332卷23期1992-2002页
Elevated lipoprotein(a) increases the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis.
313. Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial.
作者: Stephen J Nicholls.;Wei Ni.;Grace M Rhodes.;Steven E Nissen.;Ann Marie Navar.;Laura F Michael.;Axel Haupt.;John H Krege.
来源: JAMA. 2025年333卷3期222-231页
Muvalaplin inhibits lipoprotein(a) formation. A 14-day phase 1 study demonstrated that muvalaplin was well tolerated and reduced lipoprotein(a) levels up to 65%. The effect of longer administration of muvalaplin on lipoprotein(a) levels in individuals at high cardiovascular risk remains uncertain.
314. Pulmonary Vein Isolation With Optimized Linear Ablation vs Pulmonary Vein Isolation Alone for Persistent AF: The PROMPT-AF Randomized Clinical Trial.
作者: Caihua Sang.;Qiang Liu.;Yiwei Lai.;Shijun Xia.;Ruhong Jiang.;Songnan Li.;Qi Guo.;Qifan Li.;Mingyang Gao.;Xueyuan Guo.;Lihong Huang.;Nian Liu.;Chenxi Jiang.;Song Zuo.;Xiaoxia Liu.;Mengmeng Li.;Weili Ge.;Shangming Song.;Lianghua Chen.;Shuanglun Xie.;Jiangang Zou.;Ke Chen.;Xiangfei Liu.;Hesheng Hu.;Xinhua Wang.;Jinlin Zhang.;Zhaojun Wang.;Chi Wang.;Liu He.;Chao Jiang.;Ribo Tang.;Ning Zhou.;Yunlong Wang.;Deyong Long.;Xin Du.;Chenyang Jiang.;Laurent Macle.;Jianzeng Dong.;Changsheng Ma.; .
来源: JAMA. 2025年333卷5期381-389页
Success rates of pulmonary vein isolation (PVI) are modest for persistent atrial fibrillation (AF). Additional linear ablation beyond PVI has not been proved superior to PVI alone in randomized trials. Ethanol infusion of the vein of Marshall (EIVOM) facilitates ablation at the mitral isthmus and may lead to improved effectiveness of a linear ablation strategy.
315. Diagnosis and Treatment of Polycythemia Vera: A Review.
作者: Douglas Tremblay.;Marina Kremyanskaya.;John Mascarenhas.;Ronald Hoffman.
来源: JAMA. 2025年333卷2期153-160页
Polycythemia vera (PV), a myeloproliferative neoplasm characterized by an increased red blood cell mass and increased risk of thrombosis, affects approximately 65 000 people in the US, with an annual incidence of 0.5 to 4.0 cases per 100 000 persons.
318. Evaluating Performance and Agreement of Coronary Heart Disease Polygenic Risk Scores.
作者: Sarah A Abramowitz.;Kristin Boulier.;Karl Keat.;Katie M Cardone.;Manu Shivakumar.;John DePaolo.;Renae Judy.;Francisca Bermudez.;Nour Mimouni.;Christopher Neylan.;Dokyoon Kim.;Daniel J Rader.;Marylyn D Ritchie.;Benjamin F Voight.;Bogdan Pasaniuc.;Michael G Levin.;Scott M Damrauer.; .
来源: JAMA. 2025年333卷1期60-70页
Polygenic risk scores (PRSs) for coronary heart disease (CHD) are a growing clinical and commercial reality. Whether existing scores provide similar individual-level assessments of disease susceptibility remains incompletely characterized.
|